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Abstract Alpha-synuclein (aSyn) is implicated in Parkin-
son’s disease and several other neurodegenerative disorders.
To date, the function and intracellular dynamics of aSyn are
still unclear. Here, we tracked the dynamics of aSyn using
photoactivatable green fluorescent protein as a reporter. We
found that the availability of the aSyn N terminus modulates
its shuttling into the nucleus. Interestingly, familial aSyn
mutations altered the dynamics at which the protein distributes
throughout the cell. Both the A30P and A53T aSyn mutations
increase the speed at which the protein moves between the
nucleus and cytoplasm, respectively. We also found that spe-
cific kinases potentiate the shuttling of aSyn between nucleus
and cytoplasm. A mutant aSyn form that blocks S129 phos-
phorylation, S129A, results in the formation of cytoplasmic
inclusions, suggesting phosphorylation modulates aggrega-
tion in addition to modulating aSyn intracellular dynamics.
Finally, we found that the molecular chaperone HSP70 accel-
erates the entry of aSyn into the nuclear compartment.
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Introduction
Misfolded and aggregated alpha-synuclein (aSyn) is the major
component of intraneuronal inclusions known as Lewy bodies
(LBs), the pathological hallmark of Parkinson’s disease (PD)
and other synucleinopathies [1]. Despite the growing knowl-
edge on aSyn, the normal function of the protein remains
largely unclear. However, it is thought to play a role in synaptic
function and plasticity, cell differentiation and vesicular traf-
ficking [2, 3]. The subcellular distribution of aSyn is also
controversial and, although it is considered a pre-synaptic
protein, it has also been found to be evenly distributed through-
out the cells in different cellular models and in mice [4–8].
Although the majority of PD cases are idiopathic, three
missense mutations in aSyn gene (A30P, E46K and A53T),
restrained in the N-terminal domain, have been identified in
rare, autosomal-dominant inherited forms of PD, as well as
duplications and triplications of the aSyn-containing locus
[9–12]. In vitro studies revealed that the A30P mutation blocks
the membrane association and inhibits the synaptic localisation
of aSyn by destabilising its first helical structure [5, 13]. Con-
versely, A53T and E46K mutations enhance the binding to
phospholipids [14].
In the normal brain, 4% of aSyn is phosphorylated at serine
129 (S129), contrasting with 90 % of aSyn that is found to be
phosphorylated in LBs. This suggests that S129 phosphoryla-
tion might interfere with the oligomerisation and aggregation
process and contribute to the pathogenesis of PD [15, 16].
Among others, G protein-coupled receptor kinases (GRKs)
and Polo-like kinases (PLKs) were found to phosphorylate the
S129 residue of aSyn [17, 18]. Although it was proposed that
S129 phosphorylation inhibits aSyn-induced regulation of
tyrosine hydroxylase activity [19], the exact role of this post-
translational modification (PTM) in both physiological and
pathological conditions remains unclear.
Other known modifiers of aSyn aggregation are molecu-
lar chaperones, such as HSP70, which modulates the
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misfolding, aggregation and toxicity of aSyn in different
model systems [4, 20–23]. However, the mechanisms by
which HSP70 suppresses aSyn toxicity are still unclear.
The new era of time-lapse bioimaging tools combined with
GFP-derived fluorescent labels enables the characterisation of
protein kinetics in real time, providing invaluable insights into
the molecular processes in which they are involved. Photo-
activation (PA) microscopy is an emerging technique in the
field of neuroscience [24] in which a non-fluorescent mole-
cule is converted into an activated and fluorescent state by the
use of an intense and brief irradiation in a selected region of
the cell. This process enables the direct tracking of a protein
by photo-inducing fluorescence, instead of interfering with a
steady state fluorescent signal, as photobleaching (PB) meth-
ods do. The newly activated pool, obtained through the use of
an ultraviolet laser, contrasts with a background of non-
activated molecules and can be followed within the cells as
they reach their kinetics equilibrium [25, 26] (Fig. 1a).
In order to further understand the biology of aSyn, we
investigated the dynamics of aSyn between the nucleus and
cytoplasm in living cells using PA microscopy (Fig. 1b). We
found that the N-terminal of aSyn-wild-type (WT) determines
its entry into the nuclear compartment. Moreover, aSyn shut-
tles between the nucleus and cytoplasm at rates which depend
on mutations, phosphorylation state and on the presence of
HSP70. Altogether, our novel approach provides novel
insights into the biology of aSyn in living cells and may
enable the development of novel strategies for therapeutic
intervention in synucleinopathies.
Results
Blocking the N-terminal of aSyn Modulates Nuclear
Localisation
To assess whether the subcellular localisation of aSyn-WT is
affected by appending different tags to either the N or C
terminus, we performed immunocytochemistry analysis in cells
expressing either untagged aSyn-WT or GFP, Myc- or V5-
tagged versions. Both tagged and non-tagged aSyn-WT were
widely distributed throughout the cell, including the nucleus
(Fig. 2a–d). To further investigate the intracellular dynamics of
aSyn-WT, we generated fusions with a photoactivatable green
fluorescent protein (PAGFP) in order to follow the movement
of a specific pool of aSyn over time at the N or C termini (aSyn-
WT-PAGFP and PAGFP-aSyn-WT, respectively). H4 cells
were transiently transfected with plasmids encoding aSyn-
WT-PAGFP, PAGFP-aSyn-WT or PAGFP alone, as a control.
As aSyn is widely distributed in the cell, we characterised the
shuttling of aSyn between the nucleus and the cytoplasm.
Reporter proteins were photoactivated in the nucleus or cyto-
plasm for 2 s using a 405-nm laser, their cellular trafficking was
monitored and the fluorescence intensities quantified. After PA,
the PAGFP control was quickly detected in the cytoplasm or in
the nucleus after nuclear or cytoplasmic PA, respectively, reach-
ing an equilibrium of PAGFP molecules between the two
cellular compartments after 500 s. In contrast, we observed
different trafficking behaviours for aSyn-WT-PAGFP and
PAGFP-aSyn-WT (Figs. 2e and S1a; Videos S1, S2, S3, S4,
S5 and S6). aSyn-WT-PAGFP displayed different dynamics
depending on the region where PA was performed. Upon
cytoplasmic PA, aSyn-WT-PAGFP molecules entered into the
nucleus and after 1,000 s were evenly distributed between the
two subcellular compartments. Conversely, upon nuclear PA,
aSyn-WT-PAGFP was maintained in this compartment for the
remainder of the time analysed (1,000 s). In contrast with the
behaviour observed for photoactivated aSyn-WT-PAGFP,
PAGFP-aSyn-WT was not detected in the contiguous
compartment to where the PA was performed and
remained in the same subcellular region (Figs. 2e and
S1a). Immunoblotting analysis of nuclear and cytoplas-
mic extracts from cells expressing either protein con-
firmed the predominant localisation observed with
microscopy (Fig. S2a). To further validate the observa-
tions obtained using PA, we performed fluorescence
Fig. 1 Strategy for nuclear and cytoplasmic photoactivation (PA) of
PAGFP-labelled proteins. a PAGFP displays negligible fluorescence in
the spectral range where the activated fluorescence is detected. Upon
PA of a selected nuclear or cytoplasmic region with a 405 laser,
PAGFP-labelled proteins become visible and the dynamics and fate
of the activated molecules can be followed over time. b PAGFP
constructs used in this study. We used WT, A30P, E46K, A53T and
S129A aSyn variants
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recovery after PB (FRAP) experiments in H4 cells expressing
aSyn-WT-GFP, GFP-aSyn-WT or GFP alone. Upon PB of
aSyn-WT-GFP in the nucleus, we found that the recovery of
fluorescence in this compartment occurred after 500 s while
fluorescence was not significantly recovered in the cytoplasm
after PB in this region. For GFP-aSyn-WT, PB in nucleus
slightly recovered fluorescence of the reporter protein after
1,000 s (about 20 % of recovery) while no cytoplasmic recov-
ery was observed upon PB in this region (Fig. 2f; Videos S7,
8 and 9).
Altogether, our novel PA and FRAP experiments show,
for the first time, that the movement of aSyn between the
nucleus and the cytoplasm depends on the availability of the
N terminus of the protein.
Fig. 2 Blocking the N terminus
of aSyn reduces its shuttling
into the nucleus.
Immunofluorescence imaging
of H4 cells showing the
subcellular localisation of
transiently transfected aSyn a
N- and C-terminally tagged to
Myc and V5, respectively, b
tagged on both terminals with
Myc (N-terminal) and V5 (C-
terminal) and c untagged aSyn-
WT. d Live cell imaging of
aSyn N- and C-terminally
tagged to GFP. e Measurements
of fluorescence intensities over
time in the nucleus (light grey
line) and in the cytoplasm (dark
grey line) of control PAGFP
(dashed line) or fusion proteins
of aSyn-WT with PAGFP (solid
line). Values represent mean+
SD of up to 15 cells analysed
per condition. f Measurements
of fluorescence recovery after
PB over time in the nucleus
(light grey line) and in the cy-
toplasm (dark grey line) of
control GFP (dashed line) or
fusion proteins of aSyn-WT
with GFP (solid line). Scale
bars, 10 μm
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PD-Associated Mutations Alter the Subcellular Trafficking
of aSyn
Since we established a model to study aSyn intracellular
dynamics, we next investigated whether PD familial muta-
tions (A30P, E46K and A53T) in aSyn affected its traffick-
ing in the cell (Fig. 3a). In comparison to the aSyn-WT-
PAGFP, cytoplasmic aSyn-A30P- and aSyn-E46K-PAGFP
are shuttled into the nucleus in half of the time (500 s) of the
WT protein (at time points 500 and 1,000 s after PA, p
values between 0.0044 and <0.0001, respectively, α=0.05;
Table SIa). Because of this rapid movement into the nucleus,
the fluorescence intensities in the cytoplasm and nucleus
equalised earlier than in the control situation and remained
in equilibrium for several minutes. In contrast to A30P and
E46K mutants, aSyn-A53T-PAGFP remained in the com-
partment where the PA was performed, similarly to the WT
protein.
In the fusions where PAGFP was on the N terminus of
aSyn, the behaviour of A30P was similar to that of aSyn-
WT. Additionally, upon cytoplasmic PA, there was a slight
increase in molecules that remained on the nucleus (p value=
Fig. 3 Effect of aSyn
mutations on its subcellular
trafficking in living cells. a
Fluorescence intensities after
PA in the nucleus (light grey
line) and in the cytoplasm (dark
grey line) of aSyn-A30P-,
aSyn-E46K- and aSyn-A53T
PAGFP-tagged proteins (solid
line) over time. Fluorescence
intensities of photoactivated
control aSyn-WT PAGFP fu-
sion proteins are shown in
dashed line. Values represent
mean+SD of up to 15 cells
analysed per condition. b
Immunobloting analysis of total
aSyn levels in cells expressing
aSyn-WT and mutant-aSyn re-
porter proteins
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0.0185 at 1,000 s after nuclear or cytoplasmic PA, α=0.05;
Table SIa; Fig. 3a). In contrast, PAGFP-aSyn-E46K was trans-
located from the nucleus to the cytoplasm after nuclear PA (p
value=0.001 at 1,000 s after nuclear PA, α=0.05, Table SIa).
The same occurred with PAGFP-aSyn-A53T, although at a
more pronounced rate, since the fluorescence intensity was
higher in the cytoplasm than in the nucleus, starting at 700 s
after PA (p value=0.0013 at 1,000 s after PA, α=0.05; Table
SIa; and Fig. 3a). In order to investigate if the dynamics results
were influenced by differences in the levels of WT and mutant
aSyn, we performed immunobloting analysis. We verified that
the levels of total aSyn did not differ between the WT and
mutant forms of the protein (Fig. 3b). As expected, subcellular
fractionation followed by immunobloting analysis confirmed
the presence of the protein in both cytoplasmic and nuclear
compartments (Fig. S2b).
Altogether, these experiments show that A30P and E46K,
but not the A53T mutation, promoted a faster shuttling of
aSyn with a free N terminus into the nucleus when com-
pared with aSyn-WT. On the other hand, aSyn-A53T and
aSyn-E46K with a free C terminus, but not aSyn-A30P,
were delayed in the cytoplasm.
aSyn Phosphorylation by GRK5 or PLK2 Modulates
Its Subcellular Trafficking
In order to assess the role of S129 aSyn phosphorylation on
the intracellular dynamics of the protein, we co-expressed
GRK2, GRK5, PLK2 or PLK3 kinases with aSyn-WT tagged
with PAGFP on either its N- or C-terminal. The kinases tested
did not significantly alter the dynamics of aSyn-WT-PAGFP.
For aSyn-WT-PAGFP, co-expression with PLK2 did not alter
the dynamics obtained in the absence of the kinase, but
resulted in a more rapid progression towards the equilibrium
fluorescence. The other kinases tested, GRK2, GRK5 and
PLK3, neither did not induce significant differences on
aSyn-WT-PAGFP (Table SIb; Fig. S3).
In contrast, stronger effects were observed for PAGFP-
aSyn-WT. Overexpression of GRK2 did not affect the shuttling
of aSyn-WTconstructs between the nucleus and the cytoplasm
as the values of fluorescence intensity were similar in the
presence or absence of the kinase during the 1,000 s of imag-
ing. Interestingly, GRK5 promoted the trafficking of PAGFP-
aSyn-WT into the nucleus upon cytoplasmic PA, although the
difference did not reach statistical significance. Nuclear PA in
cells overexpressing GRK5 did not significantly alter the dy-
namics of PAGFP-aSyn-WT (Fig. 4a; Table SIb).
Co-expression of PAGFP-aSyn-WT with PLK2 promoted
its shuttling to the cytoplasm upon nuclear PA (similar nuclear
and cytoplasmic fluorescence levels were reached 500 s after
PA, p value=0.0141, α=0.05; Table SIb; Fig. 4a). Upon
cytoplasmic PA, PLK2 slightly accelerated the movement into
the nucleus 500 s after PA (Table SIb).
Co-expression of PAGFP-aSyn-WT with PLK3 promoted
its shuttling to the cytoplasm upon nuclear PA but this move-
ment was faster in the presence of PLK2. Although the dif-
ference was already significant 500 s after PA (p value=
0.0198, α=0.05; Table SIb), at 1,000 s the levels of fluores-
cence were still higher in the nucleus than in the cytoplasm.
Upon cytoplasmic PA, the presence of PLK3 did not alter the
dynamics of PAGFP-aSyn-WT (Fig. 4a; Table SIb). We per-
formed immunobloting analysis to investigate if the results on
the dynamics of aSyn were influenced by differences in ex-
pression in the presence and absence of the kinases tested. We
verified that the levels of total aSyn were not altered in the
presence of the kinases (Fig. 4b). As expected, we also con-
firmed that the levels of aSyn phosphorylated at S129 were
increased in the presence of both kinases (Fig. S2c).
An important difference between GRK5 and PLKs was
that the former induced a tendency of aSyn to traffic from
the cytoplasm to the nucleus and the latter had a strong
effect in promoting the trafficking of aSyn from the nucleus
to the cytoplasm.
Next, we tested the dynamics of S129A aSyn, a
phosphorylation-incompetent mutant, in order to further as-
sess the effect of S129 phosphorylation in the trafficking of
aSyn. No differences were observed on the dynamics of aSyn-
S129A-PAGFP except for the existence of more photoacti-
vated protein in the nucleus when compared with aSyn-WT
immediately after nuclear PA (Fig. S3d; Table SIa). However,
PAGFP-aSyn-S129A moved into the cytoplasm after 1,000 s
of PA if PAwas performed in the nucleus while the aSyn-WT
did not. Moreover, PAGFP-aSyn-S129A remained in the cy-
toplasm if PA was performed in that compartment (p value=
0.0099, α=0.05; Table SIa; Fig. 4c). These findings were in
agreement with the fact that both aSyn-S129A fusion proteins
were only marginally detected in the nuclear protein fraction,
in contrast to aSyn-WT (Figs. S2a, S2d and S3e), although the
total protein levels of aSyn-WT and aSyn-S129A were com-
parable (Fig. 4d; Fig. S3f).
Interestingly, we found that expression of either the N- or
C-terminal S129A fusion proteins promoted the formation
of cytosolic inclusions scattered around the nucleus (Fig. 4e;
Fig. S3g).
HSP70 Modifies the Trafficking of aSyn
HSP70 modulates the accumulation of oligomeric and
aggregated forms of aSyn in different model systems.
Thus, we next asked whether HSP70 could interfere with
the subcellular dynamics of aSyn. HSP70 did not change
the intracellular dynamics of aSyn-WT-PAGFP (Table SIb;
Fig. 5a). Conversely, upon cytoplasmic PA, PAGFP-aSyn-
WT was shuttled into the nucleus in the presence of
HSP70 within 100 s after PA (p value<0.0001, α=0.05;
Table SIb; Fig. S1b; Fig. 5a). Although the total levels of
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the protein were not altered in the presence of the chaper-
one (Fig. 5b), the levels of aSyn were higher in the
nucleus for both fusion proteins in this situation. Interest-
ingly, HSP70 was present in the nuclear fraction only
when aSyn was present (Fig. S2e). Upon nuclear PA, the
tendency was for the protein to move into the cytoplasm,
but not as quickly as in the former situation (p value at
100 s=0.7836, p value at 1,000 s=0.0014, α=0.05; Table
SIb; Fig. S1b; Fig. 5a).
In summary, HSP70 increased the shuttling of PAGFP-
aSyn-WT between the nucleus and cytoplasm.
Discussion
Here, we investigated the intracellular dynamics of aSyn in
living cells using photoactivatable GFP as a reporter. To control
for putative effects of tagging aSyn in particular domains, we
engineered fusions with PAGFP on either the N- or C-terminal
of aSyn. We found that, although both aSyn fusion proteins
were evenly spread throughout the cell, aSyn required a free N
terminus in order to move from the cytoplasm into the nucleus.
aSyn is evenly distributed throughout the cell in different in
vitro models and in mice [4–8]. The N terminus of aSyn seems
Fig. 4 Effect of S129
phosphorylation on the
subcellular dynamics of aSyn. a
Fluorescence intensities after
PA in the nucleus (light grey
line) and in the cytoplasm (dark
grey line) of PAGFP-aSyn-WT
fusion protein co-expressed
with GRK2, GRK5, PLK2 and
PLK3 (solid line) or an empty
vector (dashed lines) over time.
Fluorescence intensities of
photoactivated control PAGFP-
aSyn-WT construct after co-
transfection with an empty vec-
tor are shown by a dashed line.
Values represent mean+SD of
up to15 cells analysed per con-
dition. b Immunobloting analy-
sis of total aSyn levels in cells
co-expressing aSyn-WT report-
er proteins with the four tested
kinases. c Fluorescence intensi-
ties after PA in the nucleus
(light grey line) and in the cy-
toplasm (dark grey line) of
PAGFP-aSyn-S129A fusion
protein over time. Fluorescence
intensities of photoactivated
control PAGFP-aSyn-WT are
shown in dashed lines. Values
represent mean+SD of up to15
cells analysed per condition. d
Immunobloting analysis of total
aSyn levels in cells expressing
PAGFP-aSyn-WT or PAGFP-
aSyn-S129A. e Cytosolic
inclusions in cells expressing
PAGFP-aSyn-S129A. Images
were taken 500 s after PA in the
nucleus in order to detect the
cytosolic inclusions. Scale bar,
10 μm
1086 Mol Neurobiol (2013) 47:1081–1092
to be important for membrane binding in various model organ-
isms, ranging from yeast to rats [14, 27–29]. Although the role
of aSyn in the nucleus has not been defined, it is described to
interact with histones, inhibiting acetylation and enhancing
chromatin binding, and promoting neurotoxicity in cellular
models, in mouse nigral neurons and inDrosophila [7, 30, 31].
We also investigated whether aSyn mutations associated
with familial forms of PD altered the shuttling of aSyn between
the nucleus and cytoplasm. We found that (a) the A30P mutant
is more prone to be located in the nucleus than the aSyn-WT;
(b) the E46Kmutant loses the subcellular compartmentalisation
characteristic of the WT form; and (c) the A53T mutation is
more prone to be located in the cytoplasm than aSyn-WT.
Until recently, aSyn was thought to be an intrinsically
unfolded protein [32–34]. Nevertheless, it acquires two α-
helical structures upon interaction with vesicles, contained in
the residues 1–42 and from 45 to 98 [35–38]. In vitro studies
showed that A30P disrupts membrane binding [5, 13], per-
haps being more available to shuttle into the nucleus. Thus, it
is likely that the differences in dynamics between the aSyn
familial forms are related with the location and effect of the
mutation on the secondary structure of aSyn protein. In addi-
tion, aSyn seems to regulate actin bundling inside the cell, and
the A30P mutant affects the structure and dynamics of the
actin cytoskeleton, potentiating the formation of actin foci
[39]. Our results are also consistent with data showing that
the A30P increases the nuclear localisation of the protein [30].
A53T is described to promote the formation of cytosolic
aggregates [5, 40], which is compatible with its tendency to
be localised in the cytoplasm when compared with aSyn-WT.
PTMs are known to modulate the intracellular fate of
proteins, including their sub-cellular distribution. aSyn is
thought to have five residues prone to phosphorylation: S87,
Y125, S129, Y133 and Y136. S129 phosphorylation is the
most studied, and little information exists on the kinases
phosphorylating the other residues [41, 42]. In LBs, the ma-
jority of aSyn is thought to be phosphorylated on S129,
contrasting with almost no phosphorylation of this residue in
normal brain, However, the role of this PTM is still unclear
and controversial. Phosphorylation of aSyn by GRKs inhibits
its interaction with phospholipids [43]. In Drosophila, co-
expression of GRK2with aSyn leads to S129 phosphorylation
and enhanced aSyn neurotoxicity [44].Moreover, the levels of
specific PLKs are increased in brains of patients with Alz-
heimer’s or LB disease [45].
Here, we investigated whether a selected group of kinases,
GRK2, GRK5, PLK2 and PLK3, modulated the dynamics of
aSyn distribution in the cell. The kinases tested only affected
the dynamics of aSyn with a free C terminus, although both
fusion proteins were phosphorylated in S129. This can be due
to the fact that when the C-terminal of aSyn is free the protein is
more prone to phosphorylation at S129, resulting in a stronger
effect in its intracellular dynamics. Overall, aSyn phosphoryla-
tion by GRKs or PLKs results in different dynamics of the
protein. While GRK5 potentiates the nuclear localisation of
aSyn, PLKs modulate the shuttling of the protein between the
nucleus and cytoplasm. In particular, PLK2 modulates the
intracellular dynamics of PAGFP-aSyn-WT by increasing the
movement from the nucleus to the cytoplasm at a higher rate
than PLK3. Since aSyn has more residues prone to phosphor-
ylation, the different results obtained with GRK5 and PLKs
might reflect different phosphorylation patterns in residues
other than S129. Due to the limited availability of antibodies
these studies are still not easy to perform but as novel tools
become available one might be able to discriminate between
the effects of phosphorylation in different residues.
Interestingly, we also observed that nuclear PAGFP-aSyn-
S129A tends to move to the cytoplasm while cytoplasmic
PAGFP-aSyn-S129A remains in this subcellular compartment.
This tendency might at least partially explain the cytoplasmic
inclusions detected in the cells expressing this mutant aSyn and
suggest that the phosphorylation status on S129 is crucial for
aggregation, in agreement with recent findings in yeast, in which
S129A mutant potentiates the formation of aSyn foci [46].
Fig. 5 Modulation of the dynamics of aSyn by HSP70. a Fluorescence
intensities after PA in the nucleus (light grey) and in the cytoplasm
(dark grey) of aSyn-WT PAGFP fusion proteins co-expressed with
HSP70 (solid line) over time. Fluorescence intensities of photoacti-
vated control aSyn-WT reporters after co-transfection with an empty
vector are shown in dashed lined. Values are mean+SD of up to 15
cells analysed per condition. b Immunobloting analysis of total aSyn
levels in cells co-expressing aSyn with HSP70 or with an empty vector.
Scale bar, 10 μm
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GRKs and PLKs modulate the dynamics of aSyn in different
ways andwe did not find a consistent pattern that can explain the
role of S129 phosphorylation on the distribution of aSyn. One
possibility is that the effects of the kinases are also due to
phosphorylation of other targets in addition to aSyn. Neverthe-
less, we verified that the phosphorylation status of aSyn on S129
was related with the aggregation state of the protein.
Molecular chaperones, such as HSP70, hold great potential
as therapeutic targets due to their ability to reverse protein
aggregation and to refold or promote degradation of misfolded
proteins [47]. HSP70 was shown to inhibit formation of toxic
pre-fibrillar forms of aSyn [23] and to reduce its aggregation in
aSyn transgenic mice [22]. In flies, it was shown that co-
expression of HSP70 with aSyn-WT suppresses the loss of
dopaminergic neurons, and hence, the toxicity associated with
aSyn-WToverexpression [20]. A similar effect was observed in
yeast and in mammalian cell models, suggesting that HSP70
inhibits aSyn toxicity by binding to the exposed hydrophobic
NAC domain (non-A beta component of AD plaques; residues
61–95 of aSyn) and sequestering the protein [21, 48–50].
Here, we found that HSP70 boosted the shuttling of
PAGFP-aSyn-WT to the adjacent compartment, suggesting it
may assist aSyn to adopt a conformation that is more likely to
cross the nuclear envelope. The selective effect with PAGFP-
aSyn-WT and not with aSyn-WT-PAGFP suggests the inter-
action might take place through the C terminus of aSyn, which
is not blocked by PAGFP in this fusion protein.
In conclusion, we showed that PD-associated mutations in
aSyn, S129 phosphorylation, and HSP70 exert different
effects on aSyn trafficking within the cell (Table SII; Fig. 6).
While additional studies will be important to clarify the rela-
tive contribution of each condition, our goal was to demon-
strate the usefulness of PA microscopy for the study of aSyn
dynamics in living cells, which is not possible to achieve with
other types of approaches or with untagged protein.
Our data provide novel insights into the subcellular dynamics
of aSyn by taking advantage of a powerful method for moni-
toring protein dynamics in living cells. A complete understand-
ing of aSyn localisation, intracellular dynamics and protein–
protein interactions will be crucial for understanding the normal
function of aSyn and may enable the development of novel
strategies for intervention in PD and other synucleinopathies.
Materials and Methods
Plasmids and Cloning Procedures
aSyn-WT-PAGFP and PAGFP-aSyn-WT constructs were
generated using aSyn-GC and GN-link-aSyn pcDNA3.1
vectors [51], respectively, and verified by DNA sequencing.
In order to obtain PAGFP-aSyn-WT construct, PAGFP in
C1 vector was amplified by PCR with primers 5′TAAGC
TAGCATGGTGAGCAAGGGCGAGG3′ (which contains a
NheI restriction site) and 5′GGACTTAAGCTTGTA
CAGCTCGTCCATGCC3′ (which contains a AflII restric-
tion site and eliminates the stop codon from PAGFP).
PAGFP PCR product and GN-link-aSyn were digested with
NheI and AflII and ligated using T4 DNA ligase.
To obtain aSyn-WT-PAGFP, PAGFP in C1 vector was PCR
amplified with the primers 5′GGGTCTAGACTATTACTTG
TACAGCTCGTCCATGCC3′ (which contains a XhoI restric-
tion site and eliminates ATG site from PAGFP) and 5′GTATC
TAGACTATTACTTGTACAGCTCGTCCATGCC3′ (which
contains a XbaI restriction site and the stop codon of PAGFP).
PAGFP PCR product and aSyn-GC were digested with
XhoI/XbaI, and ligated using T4 DNA ligase.
aSyn-A30P/E46K/A53T-PAGFP and PAGFP-aSyn-
A30P/E46K/A53T constructs were generated using aSyn-
WT-PAGFP and PAGFP-aSyn-WT plasmids as backbone.
WT-aSyn was eliminated from aSyn-WT-PAGFP and
PAGFP-aSyn-WT plasmids through NheI/XhoI and AflII/X-
hoI sites, respectively. PD-associated aSyn mutant forms
were obtained from aSyn-BiFC plasmids [51] and were
inserted in the PAGFP backbone vectors.
Fig. 6 Modifiers of aSyn intracellular dynamics. aSyn-WT shuttles
into the nucleus. This is enhanced (thicker arrow) in the presence of
A30P mutation or GRK5 kinase, via phosphorylation of S129. The
mutants A53T and S129A, or overexpression of PLK2 and PLK3
kinases, promote the bidirectional shuttling between the nuclear and
the cytoplasmic compartments. E46K mutation and HSP70 chaperone
instigate a similar dynamics; however, they promote a faster shutting
into the nucleus (thicker arrow)
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Mutant S129A, which mimics the constitutively unphos-
phorylated form of aSyn, was generated by site-directed
mutagenesis from aSyn-WT constructs using primers 5′
GAGGCTTATGAAATGCCTGCTGAGGAAGGGTAT
CAAG3 ′ and 5 ′CTTGATACCCTTCCTCAGCAGG
CATTTCATAAGCCTC3′ to obtain the S129A substitution.
All constructs were generated in the pcDNA3.1 vector
and verified by DNA sequencing.
The constructs for human WT-untagged aSyn (pSI-aSyn-
WT), C-terminally tagged aSyn (aSyn-WT-V5 and aSyn-WT-
GFP), GFP-aSyn-WT and HSP70 were a kind gift of Dr.
Bradley T. Hyman and were previously described [52].
Myc-aSyn-WT-V5 and Myc-aSyn-WT have been described
previously [53]. PLK and GRK encoding plasmids were a
kind gift from Dr. Hilal Lashuel, Ecole polytechnique
Federale de Lausanne, Switzerland.
Cell Culture, Transfections and Immunocytochemistry
H4 human neuroglioma cells were maintained under stan-
dard conditions and passaged the day before transfection
[51]. Transfections with aSyn, GFP and PAGFP constructs
were performed using Fugene™ 6 reagent from Roche,
according to the manufacturer’s instructions. Immunocyto-
chemistry experiments were performed as described previ-
ously for Myc-aSyn, aSyn-V5, Myc-aSyn-V5 and untagged
aSyn constructs [51]. For PA experiments, cells were co-
transfected with a mRFP in order to identify transfected
cells. Cells were incubated for 48 h before imaging.
Live Cell Imaging
Cells were imaged using a Zeiss LSM510 META micro-
scope with a ×63 1.4 NA oil immersion objective. aSyn-WT
GFP-tagged was excited at 488 nm using an argon laser
(5 % transmission) and a 505- to 550-nm band pass filter.
For PA experiments, cells transfected with PAGFP con-
structs were first identified through a 561- to 10-nm DPSS
laser (1 % transmission) to detect mRFP (561 nm) using a
575-nm long-pass filter and photoactivated using a diode
laser line at 405 nm (100 % transmission) either in the
cytoplasm or in the nucleus, using standard procedures for
PA. PAGFP fluorescence emission was detected by excita-
tion at 488 nm (5 % transmission) using a 505- to 550-nm
band pass filter. About 500 images from each cell were
taken with an interval of 2 s, and PA was performed after
the second image; 15 cells per condition were analysed.
For FRAP experiments, cells transfected with GFP con-
structs were photobleached in the nucleus or in the cyto-
plasm using a diode laser line at 405 nm (100 %
transmission), using standard procedures for FRAP. Recov-
ery fluorescence of GFP constructs was detected by excita-
tion at 488 nm (5 % transmission) using a 505- to 550-nm
band pass filter. About 1,000 images from each cell were
taken per second, and FRAP was performed after the second
image; 15 cells per condition were analysed.
Image Analysis
The dynamics of aSyn diffusion (after PA or FRAP) was
followed by analysing time-lapse series of the PAGFP or
GFP reporter protein by measuring the fluorescence inten-
sity over time, in the nucleus and in the cytoplasm, using
ImageJ LSM toolbox plugin and LSM Image browser.
For PA analysis, the normalised nuclear fluorescence
(NF) was obtained as the following:
NFðtÞ ¼ ðNðafter PAÞ  Nðbefore PAÞÞ=
½ðNþ Cðafter PAÞÞ  ðNþ Cðbefore PAÞÞ:
The normalised cytoplasmic fluorescence (CF) was
obtained as the following:
CFðtÞ ¼ ðCðafter PAÞ  Cðbefore PAÞÞ=
½ðNþ Cðafter PAÞÞ  ðNþ Cðbefore PAÞÞ:
For FRAP analysis, the normalised NF was obtained as
the following:
NFðtÞ ¼ N after PBð Þ
 
Nþ C after PBð Þ
 
The normalised FC was obtained as the following:
NCðtÞ ¼ C after PBð Þ
  Nþ C after PBð Þ
 
Where N and C refer to nucleus and cytoplasm, respective-
ly. t=0 s refers to the time lapse immediately after PA or PB.
These normalisations corrected for the loss of fluorescence
caused by imaging both in PA and in FRAP procedures.
Statistical Analysis
The numerical results are given as mean of NF or CF±SD of
up to 15 independent experiments.
The significance of the difference between the experi-
mental and the control values of fluorescence was evaluated
at three time points, 100, 500 and 1,000 s, in the nuclear
compartment using 95 % confidence intervals (α=0.05)
through single comparisons by the two-tailed unpaired Stu-
dent’s t test followed by a Fisher’s exact test to compare
variances between the control and experimental groups.
Immunoblot Analysis
H4 total protein extracts were obtained 48-h post-
transfection using standard procedures. Briefly, cells were
washed twice in PBS and lysed in NP40 buffer (glycerol,
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10 %; HEPES, 20 mM (pH 7.9); KCl, 10 mM; EDTA,
1 mM; NP40, 0.2 %; and DTT, 1 mM) containing protease
and phosphatase inhibitors cocktail (1 tablet/10 ml; Roche
Diagnostics). After centrifugation at 16,000×g for 20 min at
4 °C, supernatants were collected (cytoplasmic extract). The
pellet was resuspended in NaCl buffer (glycerol, 20 %;
HEPES, 20 mM (pH 7.9); KCl, 10 mM; EDTA, 1 mM;
NaCl, 400 mM; and DTT, 1 mM) containing protease and
phosphatase inhibitors cocktail tablets and then centrifuged
again. After centrifugation, the supernatant corresponds to
the nuclear extract. Protein concentration was determined
using the BCA protein assay and 20 μg of protein lysates
were resolved in 12 % SDS-PAGE. Resolved proteins were
transferred to nitrocellulose membranes. After quick wash-
ing in Tris-buffered saline and 0.1 % Tween 20 (TBS-T),
membranes were blocked in 5 % non-fat dry milk in TBS
for 1 h and then incubated with primary antibodies in 5 %
BSA in TBS overnight at 4 °C. The primary antibodies used
were mouse anti-aSyn, 1:1,000 (BD Transduction); mouse
anti-GAPDH, 1:4,000 (Ambion); rabbit anti-HSP70,
1:1,000 (Assay Designs); and goat anti-LamininB C20,
1:500 (Santa Cruz Biotechnology). The membrane was then
washed three times for 10 min each in TBS-T at room
temperature and probed with ECL™ IgG horseradish
peroxidase-conjugated (HRP) anti-mouse, anti-rabbit (GE
Healthcare) or IgG HRP-conjugated anti-goat (Santa Cruz
Biotechnology) secondary antibodies (1:10,000) for 1 h at
room temperature. The membrane was then washed four
times for 15 min each with TBS-T, and the signal was
detected with an ECL chemiluminescence kit (Millipore
Immobilon Western Chemiluminescent HRP Substrate).
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